- Home
- HUYA vs MLYS Comparison
HUYA vs MLYS Comparison
Compare HUYA & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUYA
- MLYS
- Stock Information
- Founded
- HUYA 2014
- MLYS 2019
- Country
- HUYA China
- MLYS United States
- Employees
- HUYA N/A
- MLYS N/A
- Industry
- HUYA Computer Software: Programming Data Processing
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- HUYA Technology
- MLYS Health Care
- Exchange
- HUYA Nasdaq
- MLYS Nasdaq
- Market Cap
- HUYA 827.0M
- MLYS 890.6M
- IPO Year
- HUYA 2018
- MLYS 2023
- Fundamental
- Price
- HUYA $3.55
- MLYS $37.29
- Analyst Decision
- HUYA Buy
- MLYS Strong Buy
- Analyst Count
- HUYA 3
- MLYS 6
- Target Price
- HUYA $4.57
- MLYS $42.60
- AVG Volume (30 Days)
- HUYA 1.6M
- MLYS 2.6M
- Earning Date
- HUYA 11-11-2025
- MLYS 11-10-2025
- Dividend Yield
- HUYA 70.64%
- MLYS N/A
- EPS Growth
- HUYA N/A
- MLYS N/A
- EPS
- HUYA N/A
- MLYS N/A
- Revenue
- HUYA $852,782,043.00
- MLYS N/A
- Revenue This Year
- HUYA $8.09
- MLYS N/A
- Revenue Next Year
- HUYA $4.90
- MLYS N/A
- P/E Ratio
- HUYA N/A
- MLYS N/A
- Revenue Growth
- HUYA N/A
- MLYS N/A
- 52 Week Low
- HUYA $2.21
- MLYS $8.24
- 52 Week High
- HUYA $6.43
- MLYS $39.20
- Technical
- Relative Strength Index (RSI)
- HUYA 54.01
- MLYS 82.81
- Support Level
- HUYA $3.31
- MLYS $34.59
- Resistance Level
- HUYA $3.55
- MLYS $39.20
- Average True Range (ATR)
- HUYA 0.20
- MLYS 2.83
- MACD
- HUYA -0.00
- MLYS 0.73
- Stochastic Oscillator
- HUYA 46.23
- MLYS 92.13
About HUYA HUYA Inc. American depositary shares each representing one ordinary share
Established in 2011, Huya is the largest online game livestreaming company in China. Headquartered in Guangzhou, Huya mainly provides livestreamed videos on esports games such as League of Legends and Honor of Kings and collects virtual tips from viewers. Its products include the Huya Live platform in China and Nimo TV in Southeast Asia and South America. As of 2024, Huya was a subsidiary of Tencent, which owned 63% of its equity stake and held 94% of the voting power.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.